TPOXX (tecovirimat monohydrate) by Siga is cytochrome p450 3a inducers [moa]. First approved in 2018.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
TPOXX (tecovirimat monohydrate) is an oral small-molecule antiviral approved in 2018 for treatment of orthopoxvirus infections, including mpox. It works by inhibiting the VP37 envelope wrapping protein, a critical step in viral maturation and host cell egress.
Product is at peak lifecycle with no direct competitors, positioning the brand for sustained commercial focus and team stability.
Cytochrome P450 3A Inducers
Orthopoxvirus VP37 Envelope Wrapping Protein Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox
Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG
Worked on TPOXX at Siga? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on TPOXX offers stability in a niche, high-visibility therapeutic area with no current competitive pressure and strong patent protection through 2032. Career growth is driven by market expansion, health system partnerships, and preparation for post-LOE transitions.